Silence Therapeutics Announces Major ADS Public Offering
I'm LongbridgeAI, I can summarize articles.Silence Therapeutics announced a major public offering of 12,962,963 American Depositary Shares (ADS) at $13.50 per share, with an underwriter option for up to 1,944,444 additional ADSs. The company expects net proceeds of approximately $164 million, rising to $188.7 million if the option is exercised. This capital raise aims to strengthen its balance sheet and fund clinical development for its siRNA-based pipeline. The transaction closes on August 13, 2026.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The latest update is out from Silence Therapeutics ( (SLN) ).
On August 11, 2026, Silence Therapeutics entered into an underwriting agreement with Jefferies and Morgan Stanley to sell 12,962,963 American Depositary Shares in a U.S. underwritten public offering at $13.50 per ADS, with underwriters purchasing at $12.69 per ADS. The company also granted a 30-day option for up to an additional 1,944,444 ADSs, estimating net proceeds of about $164 million, or $188.7 million if the option is fully exercised, with closing expected on August 13, 2026, subject to customary conditions.
The transaction follows the company’s August 10, 2026 announcement of a proposed roughly $150 million ADS offering and its August 11, 2026 pricing release, and is being conducted under an effective shelf registration in the United States. The capital raise is set to materially strengthen Silence Therapeutics’ balance sheet as it pushes ahead with its siRNA-based pipeline, underscoring investor appetite for RNA-based therapeutics and potentially enhancing the company’s ability to fund clinical development in areas of high unmet need.
The most recent analyst rating on (SLN) stock is a Buy
with a $32.00 price target.
To see the full list of analyst forecasts on Silence Therapeutics stock,
see the SLN Stock Forecast page.
Spark’s Take on SLN Stock
According to Spark, TipRanks’ AI Analyst, SLN is a Neutral.
The score is held back primarily by weak financial performance (revenue drop, persistent losses, negative free cash flow, and negative equity), which increases funding risk. Offsetting this are strong technical momentum (price well above key moving averages with positive MACD) and constructive recent clinical trial news, though overbought signals and loss-based valuation metrics temper the outlook.
To see Spark’s full report on SLN stock,
click here.
More about Silence Therapeutics
Silence Therapeutics plc is a global clinical-stage biotechnology company focused on developing precision-engineered medicines using proprietary short interfering RNA (siRNA) technology.
Leveraging its mRNAi GOLD platform, the company is advancing a pipeline of siRNA product candidates targeting rare and common diseases with high unmet medical need, where existing treatments are limited or inadequate.
Average Trading Volume: 748,915
Technical Sentiment Signal: Buy
Current Market Cap: $728.8M